Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy.

Persistent high-risk HPV infection is the main cause of cervical cancer. The HPV oncogene E7 plays an important role in HPV carcinogenesis. Currently, HPV vaccines do not offer an effective treatment for women who already present with cervical disease, and recommended periodical cervical screenings are difficult to perform in countries and areas lacking medical resources. Our aim was to develop nanoparticles (NPs) based on poly (β-amino ester) (PBAE) and HPV16 E7-targeting CRISPR/short hairpin RNA (shRNA) to reduce the levels of HPV16 E7 as a preliminary form of a drug to treat HPV infection and its related cervical malignancy. Our NPs showed low toxicity in cells and mouse organs. By reducing the expression of HPV16 E7, our NPs could inhibit the growth of cervical cancer cells and xenograft tumors in nude mice, and they could reverse the malignant cervical epithelium phenotype in HPV16 transgenic mice. The performance of NPs containing shRNA is better than that of NPs containing CRISPR. HPV-targeting NPs consisting of PBAE and CRISPR/shRNA could potentially be developed as drugs to treat HPV infection and HPV-related cervical malignancy.

[1]  P. Barbadoro,et al.  Loop electrosurgical excision procedure and risk of miscarriage. , 2015, Fertility and sterility.

[2]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[3]  B. Cullen.  Enhancing and confirming the specificity of RNAi experiments , 2006, Nature Methods.

[4]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[5]  M. Ustav,et al.  Mechanism of Genomic Instability in Cells Infected with the High-Risk Human Papillomaviruses , 2009, PLoS pathogens.

[6]  C. Rudin,et al.  Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[7]  H. Kim,et al.  A guide to genome engineering with programmable nucleases , 2014, Nature Reviews Genetics.

[8]  Kai Xu,et al.  shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy , 2016, Oncotarget.

[9]  W. Mark Saltzman,et al.  Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA , 2009, Nature materials.

[10]  Jordan J. Green,et al.  Synthesis and application of poly(ethylene glycol)-co-poly(β-amino ester) copolymers for small cell lung cancer gene therapy. , 2016, Acta biomaterialia.

[11]  A. Psyrri,et al.  E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. , 2009, Journal of the National Cancer Institute.

[12]  X. Fang,et al.  Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism , 2015, Nature Genetics.

[13]  Jordan J. Green,et al.  Bioreducible Cationic Polymer-Based Nanoparticles for Efficient and Environmentally Triggered Cytoplasmic siRNA Delivery to Primary Human Brain Cancer Cells , 2014, ACS nano.

[14]  S. Goldie,et al.  Cost Effectiveness and Resource Allocation Open Access Estimating the Cost of Cervical Cancer Screening in Five Developing Countries , 2006 .

[15]  R. Bhargava,et al.  The role of human papillomavirus in nongenital cancers , 2013, CA: a cancer journal for clinicians.

[16]  J. Cuzick,et al.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial , 2017, The Lancet.

[17]  P. Beard,et al.  Human Papillomavirus Type 16 E2 Protein Has No Effect on Transcription from Episomal Viral DNA , 2003, Journal of Virology.

[18]  W. Walther,et al.  Vectors and strategies for nonviral cancer gene therapy , 2016, Expert opinion on biological therapy.

[19]  J. T. Cox,et al.  American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2007, CA: a cancer journal for clinicians.

[20]  D. Segal,et al.  The generation of zinc finger proteins by modular assembly. , 2010, Methods in molecular biology.

[21]  Xu Li,et al.  In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line , 2016, Translational oncology.

[22]  L. Meng,et al.  RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53 , 2008, Apoptosis.

[23]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[24]  Charles H Jones,et al.  Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. , 2015, Biomaterials.

[25]  Cai-yun Zhou,et al.  Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. , 2013, Antiviral research.

[26]  K. Münger,et al.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A , 1988, Cell.

[27]  Pere Dosta,et al.  Oligopeptide-terminated poly(β-amino ester)s for highly efficient gene delivery and intracellular localization. , 2014, Acta biomaterialia.

[28]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[29]  Jane J. Kim,et al.  Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus , 2017, Journal of the National Cancer Institute.

[30]  G. Bogani,et al.  The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. , 2018, Critical reviews in oncology/hematology.

[31]  Zhangyong Hong,et al.  Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles , 2017, Advanced functional materials.

[32]  D. Kalvakolanu,et al.  Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo. , 2013, Cancer letters.

[33]  Sue J Goldie,et al.  Health and economic implications of HPV vaccination in the United States. , 2008, The New England journal of medicine.

[34]  D. Hanahan,et al.  Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Antonia A. Dominguez,et al.  Transcriptional regulation of hepatic lipogenesis , 2015, Nature Reviews Molecular Cell Biology.

[36]  N. Coleman,et al.  Integration of high‐risk human papillomavirus: a key event in cervical carcinogenesis? , 2007, The Journal of pathology.

[37]  J. Sunshine,et al.  Differential polymer structure tunes mechanism of cellular uptake and transfection routes of poly(β-amino ester) polyplexes in human breast cancer cells. , 2014, Bioconjugate chemistry.

[38]  S. Resch,et al.  Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries , 2016, PloS one.

[39]  M. Chorilli,et al.  Highlights in nanocarriers for the treatment against cervical cancer. , 2017, Materials science & engineering. C, Materials for biological applications.

[40]  F. Talamantes,et al.  Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. , 2000, Cancer research.

[41]  S. Francis,et al.  Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. , 2010, Vaccine.

[42]  Y. L. Liu,et al.  Effects of loop electrosurgical excision procedure or cold knife conization on pregnancy outcomes. , 2013, European journal of gynaecological oncology.

[43]  Yoshimitsu Takahashi,et al.  In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. , 2014, Biochemical and biophysical research communications.

[44]  J. S. Suk,et al.  Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy , 2015, Proceedings of the National Academy of Sciences.

[45]  Robert Langer,et al.  Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[46]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[47]  P. Coursaget,et al.  Inhibition of cervical cancer cell growth by human papillomavirus virus–like particles packaged with human papillomavirus oncoprotein short hairpin RNAs , 2009, Molecular Cancer Therapeutics.

[48]  G. Kwon,et al.  pH- and ion-sensitive polymers for drug delivery , 2013, Expert opinion on drug delivery.

[49]  Martin G Pomper,et al.  Student award winner in the Ph.D. category for the 2013 society for biomaterials annual meeting and exposition, april 10-13, 2013, Boston, Massachusetts : biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. , 2013, Journal of biomedical materials research. Part A.

[50]  Joakim Dillner,et al.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer. , 2007, The New England journal of medicine.

[51]  Y. Shin,et al.  Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer , 2015, Journal of clinical medicine.

[52]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[53]  Yong-Hee Kim,et al.  Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[54]  M. Saravanan,et al.  Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV). , 2018, Pharmaceutical nanotechnology.

[55]  E. Franco,et al.  Persistent human papillomavirus infection and cervical neoplasia. , 2002, The Lancet. Oncology.

[56]  Karl Münger,et al.  Biological activities and molecular targets of the human papillomavirus E7 oncoprotein , 2001, Oncogene.

[57]  R. Rangel-ColmeneroBlanca,et al.  Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7. , 2014 .

[58]  Alfredo Quiñones-Hinojosa,et al.  Biodegradable Polymeric Nanoparticles Show High Efficacy and Specificity at DNA Delivery to Human Glioblastoma in Vitro and in Vivo , 2014, ACS nano.

[59]  H. Bradlow,et al.  Diindolylmethane Inhibits Cervical Dysplasia, Alters Estrogen Metabolism, and Enhances Immune Response in the K14-HPV16 Transgenic Mouse Model , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[60]  Jing Liu,et al.  Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy. , 2018, International journal of pharmaceutics.

[61]  D. Merlin,et al.  Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. , 2014, Gastroenterology.

[62]  D. Grainger,et al.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption. , 2012, Advanced drug delivery reviews.

[63]  T. Kanazawa,et al.  Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. , 2013, Biomaterials.

[64]  Seung‐Woo Cho,et al.  Bacterial tRNase–Based Gene Therapy with Poly(β‐Amino Ester) Nanoparticles for Suppressing Melanoma Tumor Growth and Relapse , 2018, Advanced healthcare materials.

[65]  Ding Ma,et al.  Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells , 2014, BioMed research international.